

The role of medical oncologists in multidisciplinary cancer care teams.

Yeter Ezgi*

Department of Health Science, University College Dublin, Ireland

Introduction

Cancer care has evolved significantly over the past few decades, transitioning from a primarily solo practice approach to a comprehensive, team-based strategy. In this multidisciplinary landscape, medical oncologists play a pivotal role, acting as both leaders and collaborators to ensure patients receive holistic and tailored treatment plans. This article explores the various responsibilities and contributions of medical oncologists within multidisciplinary cancer care teams. Medical oncologists are often at the forefront of coordinating patient care, serving as the central point of contact for patients and their families. They work closely with surgeons, radiation oncologists, pathologists, radiologists, and other healthcare professionals to develop and implement individualized treatment plans [1, 2].

This coordination is crucial in managing the complexities of cancer treatment, which often involves multiple modalities and phases, including surgery, chemotherapy, radiation therapy, and palliative care. One of the primary responsibilities of medical oncologists is to devise personalized treatment plans based on the latest research and clinical guidelines. They consider various factors such as the type and stage of cancer, genetic markers, patient health status, and preferences. By leveraging their expertise in chemotherapy, immunotherapy, targeted therapy, and hormone therapy, medical oncologists tailor treatments to maximize efficacy and minimize side effects, ensuring that each patient receives the most appropriate care [3, 4].

Medical oncologists are instrumental in advancing cancer treatment through clinical trials and research. They identify suitable candidates for trials, explain the potential risks and benefits, and monitor patients throughout the study. Their involvement in research helps bring new therapies from the laboratory to the clinic, providing patients with access to cutting-edge treatments that may not yet be widely available. This research is vital for the continuous improvement of cancer care and the development of more effective and less toxic treatments. The management of side effects and complications arising from cancer treatments is another critical aspect of a medical oncologist's role. They are adept at identifying and addressing adverse reactions to therapies, ensuring that patients maintain the best possible quality of life during and after treatment. This involves close monitoring, dose adjustments, and supportive care measures such as pain management, nutritional support, and psychosocial interventions [5, 6].

Effective communication is a cornerstone of multidisciplinary cancer care, and medical oncologists play a key role in facilitating this dialogue. They ensure that all team members are informed about the patient's treatment plan, progress, and any changes in their condition. Additionally, medical oncologists provide emotional support and education to patients and their families, helping them navigate the often overwhelming journey of cancer treatment. This compassionate care is essential for patient-centered care and helps build trust and rapport with patients. Medical oncologists often serve as advocates for their patients, ensuring that their needs and preferences are prioritized in the treatment planning process. They work to overcome barriers to care, such as insurance issues, access to medications, and coordinating with other healthcare providers [7, 8].

By advocating for their patients, medical oncologists help ensure that each individual receives timely and appropriate care, tailored to their unique circumstances. In a multidisciplinary team, the expertise of medical oncologists enhances the overall effectiveness of cancer care. Their insights into the latest treatment modalities and their ability to manage complex cases contribute significantly to the team's decision-making process. Regular tumor board meetings and case discussions are common platforms where medical oncologists share their knowledge, fostering a collaborative environment that benefits patient outcomes [9, 10].

Conclusion

Medical oncologists are integral to the success of multidisciplinary cancer care teams. Their expertise in coordinating care, personalizing treatment plans, leading research, managing side effects, facilitating communication, advocating for patients, and enhancing team collaboration ensures that patients receive comprehensive and compassionate care. As cancer treatment continues to evolve, the role of medical oncologists will remain central to delivering high-quality, patient-centered care that addresses the multifaceted needs of cancer patients.

References

1. Chen QY, Costa M. A comprehensive review of metal-induced cellular transformation studies. *Toxicol Appl Pharmacol.* 2017;331:33-40.
2. Hull LA. Progress towards a unified theory of the mechanisms of carcinogenesis: Role of epigenetic mechanisms. *Med Hypotheses.* 1980;63:5-47.

*Correspondence to: Yeter Ezgi, Department of Health Science, University College Dublin, Ireland, E mail: yeter@ezgi.ie

Received: 08-Mar-2024, Manuscript No. AAMOR-24-136484; Editor assigned: 09-Mar-2024, PreQC No. AAMOR-24-136484(PQ); Reviewed: 23-Mar-2024, QC No. AAMOR-24-136484; Revised: 28-Mar-2024, Manuscript No. AAMOR-24-136484(R); Published: 04-Apr-2024, DOI:10.35841/aamor-8.2.221

3. Slaughter DP, Southwick HW, Smejkal W, et al. "Field cancerization" in oral stratified squamous epithelium Clinical implications of multicentric Origin. *Cancer*. 1953;6:963-68.
4. Tung PY, Knoepfler PS. Epigenetic mechanisms of tumorigenicity manifesting in stem cells. *Oncogene* 2014;34:2288-96.
5. Wallace DR, Buha Djordjevic A. Heavy metal and pesticide exposure: a mixture of potential toxicity and carcinogenicity. *Curr Opin Toxicol*. 2020;19:72-79.
6. Ljungberg B, Campbell SC, Choi HY, et al. The epidemiology of renal cell carcinoma. *Eur Urol*. 2011;60(4):615-21.
7. Yang DC, Chen CH. Potential new therapeutic approaches for renal cell carcinoma. *Semin Nephrol*. 2020;40(1): 86-97.
8. TH Oh, YH Lee, IY. Seo, et al. Diagnostic efficacy of contrast-enhanced ultrasound for small renal masses. *Korean J Urol*. 2014;55(9):587-92.
9. Perdon S, Autorino R, Gallo L, et al. Renal cell carcinoma with solitary toe metastasis. *Int J Urol*. 2005;12(4):401-4.
10. Leibowitz-Amit R, Israel A, Gal M, et al. Association between the absolute baseline lymphocyte count and response to neoadjuvant platinum-based chemotherapy in muscle-invasive bladder cancer. *Clin Oncol*. 2016;28(12):790-96.